Chidamide is an approved drug for treatment of the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL). Chidamide was developed by Shenzhen Microchip Biological Sci. & Tech. Co. Ltd..
The API has now reached off-patent status, after being launched in 2014.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Chidamide and many others, contact info@pharmacheminvestor.com